Changed date for the Q3 2007 report

Changed date for the Q3 2007 report

The reporting date for the Orexo interim report January-September 2007 has been
changed. The report will now be published on October 23, 2007.

For further information, please contact:

Zsolt Lavotha, President and CEO
Tel: +46-18-780 88 12, e-mail: zsolt.lavotha@orexo.com 

Claes Wenthzel, Executive Vice President and CFO
Tel: +46-18-780 88 44, e-mail: claes.wenthzel@orexo.com   


NOTES TO EDITORS:

About Orexo 
Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo´s drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, and
three under formulation development. 

Orexo is listed on the OMX Nordic List Mid Cap (ticker: ORX). 

www.orexo.com